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Abstract (229 words) 
 
Objectives: The risk of developing active TB is greater in those receiving 
haemodialysis. This study aimed to describe the incidence of active tuberculosis 
among patients referred for management of kidney disease and dialysis in a high 
incidence UK city, with the purpose of informing latent TB testing and treatment 
practice.  
 
Methods: Information from the tuberculosis register was cross-referenced with 
the Department of Renal Medicine patient information system. All patients seen 
between 1st January 2005 and 1st October 2016 were included in the analyses 
with the exception of those with prior TB.  
 
Results: 68 cases of active TB were identified, an incidence of 126/100,000 
patient-years (95% CI 97-169). Incidence was lowest in those with CKD 1 or 2 
and rose as high as 256/100,000 patient-years (95% CI 183-374) in those 
receiving renal replacement therapy. 48% of cases were pulmonary and 87% of 
TB patients gave their ethnicity as either black/black British or Asian/Asian 
British, significantly more than in the non-TB renal group. Cases occurred 
steadily over the time period in which patients were in the cohort. 
 
Conclusion: TB incidence was very high among those receiving renal 
replacement therapy or CKD 4 or 5. Most cases occurred in those of an 
Asian/Asian British or black/black British background. Testing and treating such 
patients for latent TB is justified and should include those who have been 
receiving renal replacement therapy for some years.  
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Introduction 
It is estimated that around one quarter of the world’s population is infected with 
tuberculosis (TB) (1). Over a lifetime a healthy individual with latent TB has 10-
15% chance of developing active TB infection. This risk is greatly increased in 
those with certain forms of immunosuppression or co-morbidity. For example, it 
doubles or trebles in those receiving TNF-antagonists for treatment of conditions 
such as rheumatoid arthritis and psoriasis(2). This has led the UK Medicine and 
Healthcare Regulatory Agency to recommend that all patients in whom 
treatment with TNF-antagonists is being considered are first screened for latent 
TB and treated if necessary(3).  
 
Patients receiving haemodialysis are known to be at increased risk of latent TB 
reactivation(4). Some studies estimate this as great as 25 times that of an 
otherwise healthy individual(5). Even patients experiencing acute kidney injury 
and requiring short spells of dialysis(6) or those with chronic kidney disease 
(CKD) not yet requiring it have been shown to have higher rates of incident 
active TB(7). There is at present little consensus on whether to screen dialysis 
patients for latent TB routinely. Current UK advice recommends against the 
practice suggesting instead that those at high risk should be considered on a 
case-by-case basis(8) whereas more recent guidance from the World Health 
Organization recommends testing for all patients receiving dialysis(9).  
 
Birmingham is the UK’s second city. 24% of its population was born overseas, 
mostly in India and Pakistan (Office for National Statistics 2011). It has a TB 
incidence of 29 per 100,000/year, one of the highest outside of London, with 
approximately 350 active cases treated each year, 75% of whom were born 
overseas. This compares with a rate of 10.2 per 100,000/year in 2017 in England 
(10). Heart of England NHS Foundation Trust provides renal care and dialysis 
services to the population of East Birmingham and Solihull. In line with national 
guidance it does not routinely screen for latent TB. This study aimed to describe 
the incidence of active TB within patients referred for management of kidney 
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disease and dialysis with the purpose of informing the unit’s latent TB testing 
and treatment practice. 
 
Methods 
The Heart of England NHS Foundation Trust TB register was cross-referenced 
with the Department of Renal Medicine patient information system. This holds 
basic information on all patients referred to the renal department with kidney 
disease, as well as those receiving peritoneal or haemodialysis. All patients seen 
between 1st January 2005 and 1st October 2016 were included in the analyses 
with the exception of those with prior TB. Patients were considered to have 
come under the care of the renal unit on the earlier of the date of their first 
estimated glomerular filtration rate (eGFR) record or their first entry in their 
electronic patient record. Eligible renal unit patients were followed up until the 
earliest of the following dates: patient diagnosed with TB (incident case), patient 
death, patient transferred out of renal unit, and 1st October 2016. CKD stage was 
taken from a single eGFR result or evidence of dialysis. Patient follow-up was 
split by CKD stage and dialysis status (pre/post). All analyses were carried out 
using Stata 14.2. 
 
Ethics 
As a service improvement project using data already available to us in the course 
of routine clinical care, ethical approval was not required. 
 
Results 
Demographics 
There were 8767 patients within the renal cohort representing 53,833 patient 
years. The median age at entry was 66 years (mean 62 years). 71% were white, 
18% Asian/Asian British and 5% black/black British. 56% were male. By the end 
of follow-up 24% of the cohort was at CKD 3 or less, 45% were at CKD 4 and not 
receiving renal replacement therapy, with 31% of the cohort receiving some 
form of renal replacement therapy. 
 
Cases of active tuberculosis 
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68 patients developed tuberculosis during the time period studied. Those 
developing TB were younger at entry to the renal cohort (mean age 55 versus 
62.5, p<0.001) and had higher death rates (23.5% vs 37%, p=0.022) than those 
who did not develop TB. They were also significantly more likely to identify as 
Asian/Asian British or black/black British (p<0.001) and to have received 
intravenous iron therapy (33.8% vs 20.3%, p=0.006). There was no statistically 
significant association with being diabetic (table 1). Most patients had no 
identifiable additional immunosuppression with 11 being on 
immunosuppression drugs for their primary disease and 2 with diagnoses of 
HIV. 
 
Of the 68 cases there were 11 instances of intrathoracic lymph node disease and 
33 pulmonary cases. 22 patients were smear positive, of which 86% were 
culture positive. Just 1 of the 31 smear negative sputum specimens was culture 
positive. Among the 23 culture positive specimens one was resistant to isoniazid 
alone, and one was multi-drug resistant (to rifampicin and isoniazid). 
 
8 of the 16 recorded deaths among TB patients occurred within 2 years of 
starting TB treatment. 2 deaths were directly attributable to TB, 1 had no 
information available and the remaining were due to unrelated respiratory or 
cardiovascular disease. 
 
Molecular epidemiology of active TB cases 
MIRU-VNTR genotyping was available for 20 of the 23 culture positive 
specimens. For the nine specimens prior to 2010, this was 15-locus, and later, 24 
locus. In addition 12 of these had had whole genome sequencing (WGS) 
performed as part of a separate study. Whilst MIRU-VNTR suggested that 3 
patient pairs might have had related TB infections this was not supported by 
single nucleotide polymorphism  typing from WGS. 1 patient without WGS data 
available had a similar MIRU-VNTR type to one other but no epidemiological 
links were identified during contact tracing. 4 of the 20 cases were identified by 
WGS as part of separate larger UK tuberculosis clusters. 
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Incidence of active tuberculosis 
The overall incidence of TB within the renal cohort was 126/100,000 patient-
years (95% CI 97-169). It was as low as 92/100,000 (95% CI 49-191) in those 
with CKD 1 or 2 and as high as 257/100,000 patient years (95% CI 183-374) in 
those receiving renal replacement (figure 1). There was no specific time point at 
which TB cases were more likely to occur, with cases occurring steadily over the 
time individuals spent in the cohort (figure 2). TB incidence was significantly 
higher in those patients who received intravenous iron therapy compared to 
those who did not (table 1). 
 
Discussion 
It is recognized that those patients with advanced kidney disease or undergoing 
renal replacement therapy are at high risk of developing active TB(4). Over the 
approximately 10 years of data in our study we identified 68 cases of active TB, 
equating to an overall incidence of 126/100,000 patient-years in the cohort 
(95% CI 97-169). Whilst not directly comparable, Public Health England reports 
an overall rate of 29/100,000 people per year for the City of Birmingham. 
Incidence was lowest in those with CKD 1 or 2 and rose as high as 256/100,000 
patient-years (95% CI 183-374) in those receiving renal replacement therapy. 
We also noted a significant association with the receipt of intravenous iron 
therapy. Iron is a co-factor supporting mycobacterial growth(11) and whilst it is 
theoretically possible there is a direct link between iron use and the emergence 
of active tuberculosis, use of iron may simply be associated with more significant 
renal disease and debilitation.  
 
Patients developing active TB did so gradually over their time in the study 
cohort. There was no apparent point of increased risk, for example around the 
time of starting dialysis. This would suggest that there is benefit in testing those 
who are already long established on renal replacement therapy when launching 
a new testing programme. 
 
48% of cases were pulmonary and each of these cases prompted lengthy and 
expensive contact tracing exercises. Whilst there were no reported cases of TB 
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transmission, dialysis units are potentially high-risk environments, gathering 
together immunodeficient individuals for several hours each week. Transmission 
has been reported elsewhere(12) and each active case on a dialysis unit results 
in large and expensive screening exercises. These could well be avoided if 
patients with latent TB were identified and treated on entering dialysis 
programmes.  
 
Guidance regarding testing for latent TB in this population varies, recognizing 
the differences in incidence between patient groups or geographical areas (1,6) 
and the limitations of current diagnostics in this context. 87% of TB patients in 
our cohort gave their ethnicity as either black/black British or Asian/Asian 
British, significantly more than in the non-TB renal group. Latent TB testing 
would be employed most cost-effectively in these groups. Our population did not 
include a significant numbers of Caucasians from countries with a high TB 
incidence. Where costs are a constraint it would be appropriate to focus testing 
and treating those of an ethnicity, or country of origin, associated with a high risk 
of incident TB. In addition whilst the apparent association with iron 
administration cannot be assumed to be causal the need for its use certainly 
indicates a patient group at risk of TB. Testing should be considered in all 
patients with advanced renal failure regardless of the need for renal replacement 
therapy. 
 
The method by which a diagnosis of latent TB is made in this population is not 
straightforward. The sensitivity of tuberculin skin testing is reduced – as is to a 
lesser extent that of the interferon-gamma release assay (IGRA)(13) – in those 
receiving dialysis. In the general population T-spot and Quantiferon (QFT) have a 
sensitivity of between 68-90% and 52-70% respectively with a specificity of 
97% for both(14,15). In comparison a meta-analysis of studies examining latent 
TB diagnosis in dialysis patients gave a pooled sensitivity of around 50% and 
specificity of 65% for both tests in the dialysis population(16,17) – with TSTs 
giving a pooled sensitivity of 31%. The low sensitivity of IGRAs must be 
understood in the context of the lack of gold standard for the diagnosis of latent 
TB. The studies from which these figures were derived varied in how they 
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defined latent TB, using one or a combination of history of treated TB, history of 
TB contact, and radiological evidence of past TB. The sensitivity of QFT is as high 
as 71% if measured against the more liberal standard of any one, or multiple, of 
those risk factors. It is clear that IGRAs are not a rule-out test for latent TB. A 
negative test in a patient highly likely to have been exposed to TB – for example 
with chest X-ray changes consistent with past TB infection  or recent confirmed 
TB contact – may still benefit from treatment and a clinical assessment of TB risk 
is indicated. Treatment is not without its risks and such patients are likely to be 
best managed on a case-by-case basis by those with experience in tuberculosis. If 
not treated they should be encouraged to report the subsequent development of 
TB symptoms promptly. 
 
Beyond sensitivity and specificity there are practical issues with IGRA result 
interpretation. Firstly results may be reported as “indeterminate” due to either a 
high background level of interferon-gamma activity within the negative control 
or low response to the positive control(18). T-spot produces fewer 
indeterminate results than QFT (4.8% vs 12.6%) among dialysis patients(16) 
which may favour its use in this patient group. Secondly, serial IGRA tests among 
renal patients over time demonstrates a variable level of conversion and 
reversion unrelated to treatment for latent TB(19). A stronger initial response is 
associated with sustained positivity and may have a role in deciding who should 
be treated(20). Sensitivity can be improved by a repeat testing protocol. In one 
small study those patients with 2 or more positive IGRAs conducted over a short 
time period were more likely to develop active TB over the follow-up period(21).  
 
There were a number of limitations to this study. It was retrospective and 
certain assumptions had to be made with respect to the data. Patients were 
assigned to a CKD stage by a single eGFR result and some may have been 
misclassified. The assumptions made in defining the observation period may 
have led to time overestimates if patients were not resident in the Birmingham 
and Solihull region for the entire period. TB cases diagnosed in another district 
would not have been included as incident TB cases which may have led to an 
underestimate of true TB incidence. Finally this study has reported a single 
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incidence derived from a 10-year period. Over this time TB rates have fluctuated 
from an English peak of 15.6/100,000/year in 2011 before declining to current 
levels. 
 
In conclusion our data indicates that testing and treating for latent TB is justified 
in dialysis recipients of an ethnicity or country of origin associated with a high 
risk of incident TB even if well-established on dialysis. It should also be 
considered in all patients with advanced renal failure regardless of the need for 
renal replacement therapy – particularly those requiring intravenous iron. It is 
less clear whether there is a benefit in testing and treating lower risk patients. 
Our approach to the use of immunosuppressive biological therapies would 
suggest they should be but the number needed to test and treat in order to 
prevent a case of active TB is not known. Current WHO guidance is supportive of 
universal testing of dialysis recipients(9). 
 
IGRAs are preferred over TST for reasons of sensitivity with T-spot likely to be 
most useful in clinical practice due to its lower rate of indeterminate results. 
There is insufficient evidence to suggest a serial testing strategy at present but it 
may have a role in the management of those patients who are reluctant to take 
treatment on the basis of a single result, or in whom treatment would be 
potentially complex. The relatively low sensitivity of IGRAs must be considered 
and testing should be combined with a thorough clinical risk assessment. The 
prospective validation of a combined IGRA and clinical risk assessment protocol 
is an important area for future research. Those at high risk of latent TB with 
negative tests – or positive tests electing not to take treatment – should be 
discussed with a specialist and encouraged to report the later development of 
any symptoms suspicious for TB. 
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Table 1: Comparison of renal cohort patients, with and without incident TB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Chi-
square 
test for count data; Wilcoxon rank-sum test for continuous data  
  Incident TB No incident TB significance* 
Renal patients (%) 68 (0.8%) 8699 (99.2%)   
        
Mean age at entry  (SD) 55.0 (16.0) 62.5 (18.7) p<0.001 
Median age at entry  (IQR) 55.1 (39.6-69.1) 67.0 (50.4-77.0)   
        
Mean age at exit  (SD) 60.2 (17.2) 66.3 (18.0) p=0.003 
Median age at exit  (IQR) 60.0 (46.6-75.0) 70.4 (54.6-80.3)   
        
Male (%) 36 (53%) 4883 (56%) p=0.597 
        
Ethnicity (%)       
White 7 (10.3%) 6260 (72.0%)   
Asian/Asian British 53 (77.9%) 1556 (17.9%)   
Black/Black British 7 (10.3%) 446 (5.1%)   
Other Ethnic Groups 0 (0.0%) 64 (0.7%)   
Mixed 0 (0.0%) 51 (0.6%)   
Unknown 1 (1.5%) 322 (3.7%) p<0.001 
        
Mean follow-up time in renal 
unit in years (SD)  10.2 (4.6) 8.3 (6.2) p=0.001 
Median follow-up time in renal 
unit in years (IQR)  10.6 (7.7-13.2) 7.9 (2.8-12.2)   
        
Deaths (%) 16 (23.5%) 3218 (37.0) p=0.022 
        
Mean age at death in years 
(SD) 67.4 (16.1) 74.9 (12.7) p=0.003 
Mean age at death in years 
(SD) 71.7 (53.1-80.9) 77.6 (68.5-83.9)   
        
CKD stage at exit (%)       
1 or 2 8 (11.8%) 717 (8.3%)   
3 11 (16.2%) 1368 (15.8%)   
4+ pre-dialysis 22 (32.4%) 3903 (44.9%)   
4+ post-dialysis 27 (39.7%) 2711 (31.2%) p=0.175 
        
IV iron treatment (%) 23 (33.8%) 1764 (20.3%) p=0.006 
        
Mean dialysis duration in 
years since entry to renal unit 
(SD) 6.3 (3.6) 6.0 (6.8) p=0.050 
Median dialysis duration in 
years since entry to renal unit 
(IQR) 6.6 (3.6-8.3) 3.8 (1.2-8.3)   
        
Diabetes at exit (%) 23 (33.8%) 2237 (25.7%) p=0.128 
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Table 2 
TB cases: clinical and microbiological features 
 
    Number 
TB site  
Pulmonary 33 
Pleural 1 
Abdominal 3 
Intrathoracic LN 11 
Extrathoracic LN 1 
Miliary 4 
Spinal 3 
Other (joint, pericardial, urinary, unknown) 12 
  
Diagnostics  
Smear positive (n culture positive) 22 (19) 
Smear negative (n culture positive) 31 (1) 
Histology (n culture positive) 8 (3) 
  
Drug sensitivity (from 23 culture positive)  
Fully sensitive 21 
INH mono-resistant 1 
RIF resistant or MDR 1 
  
Treatment duration  
6 months 40 
7-9 months 7 
10-12 months 9 
13-24 months 3 
Not treated 1 
Unknown 7 
  
Immunosuppression 
 None 52 
Immunosuppressive drugs 11 
HIV 2 
Not known 3 
  
Renal diagnosis  
Diabetes 15 
Glomerulonephritis 8 
Hypertension 16 
HIV nephropathy 1 
Other 14 
Unknown 14 
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Figure 1 
TB incidence among renal patients in East Birmingham, UK.  
Y-axis: cases/100,000 person years (95% confidence intervals) 
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Figure 2: TB-free survival among renal cohort patients with CKD 4/5 or receiving renal 
replacement therapy. 
 
 
 
Time starts from earliest of CKD 4/5, dialysis or first seen in clinic with CKD 4/5/dialysis 
 
 
